Of note, the AHR/SRC axis has recently been discovered as a new therapeutic vulnerability that triggers resistance to BRAF (B-Raf proto-oncogene, serine/threonine kinase) inhibitors in melanoma [123]. Here, BRAF is linked to melanoma.